EyePoint Pharmaceuticals, Inc. / Fundamentals

    Income statement

    Net revenue
    €48.08M
    Cost of goods sold
    €3.22M
    Gross profit
    €44.86M
    SG&A expenses
    €44.91M
    R&D expenses
    €138.40M
    EBITDA
    -€130.74M
    D&A
    €1.49M
    EBIT
    -€138.46M
    Interest expenses
    €12.01K
    EBT
    -€125.86M
    Tax expenses
    €77.22K
    Net income
    -€125.94M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    -€28.33M
    Changes in working capital
    -€1.11M
    Operating cash flow
    -€127.13M
    Capex
    €2.69M
    Other investing cash flow
    -€133.29M
    Net investing cash flow
    -€172.15M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €136.21M
    Debt repayment
    -€120.12K
    Other financing cash flow
    €9.93M
    Net financing cash flow
    €139.82M
    Foreign exchange effects
    €0.00
    Net change in cash
    -€159.34M
    Cash at end of period
    €73.19M
    Free cash flow
    -€124.45M

    Balance sheet

    Cash and cash equivalents
    €73.07M
    Cash and short-term investments
    €273.01M
    Total receivables
    €379.24K
    Inventory
    €1.83M
    Other current assets
    €5.34M
    Total current assets
    €280.55M
    Property, plant & equipment
    €25.36M
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €5.17M
    Total non-current assets
    €30.53M
    Total assets
    €311.08M
    Accounts payable
    €14.09M
    Short-term debt
    €1.52M
    Other current liabilities
    €15.77M
    Total current liabilities
    €35.76M
    Long-term debt
    €19.15M
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €151.87K
    Total non-current liabilities
    €19.30M
    Total liabilities
    €55.06M
    Common stock
    €59.20K
    Retained earnings
    -€787.83M
    Other equity
    €791.93K
    Total equity
    €256.02M
    Total liabilities and shareholders' equity
    €311.08M

    Company information

    Market capitalization
    €565.80M
    Employees
    165
    Enterprise Value
    €545.16M

    Company ratios

    Gross margin
    93.3% Much worse than peer group: 1,569,383,908,285,939,400.0%
    EBITDA margin
    -271.9% Much worse than peer group: 10,655,874,544,827,208,000.0%
    EBIT margin
    -287.9% Much worse than peer group: 3,610,547,788,176,909,000.0%
    EBT margin
    -261.8% Much worse than peer group: 10,940,544,724,014,755,000.0%
    Net margin
    -261.9% Much worse than peer group: 10,958,360,016,292,917,000.0%
    ROE
    -49.2% Much better than peer group: -181.8%
    ROA
    -40.5% Much better than peer group: -165.0%
    Asset turnover
    15.5% Worse than peer group: 34.2%
    FCF margin
    -270.0% Much better than peer group: -6,018,246,406,126,677,600.0%
    FCF yield
    -22.9%
    Efficiency ratio
    371.9%
    Net sales per employee
    €291.42K
    Net income per employee
    -€763.26K

    Notifications